(The Center Square) – Nine more companies have joined President Donald Trump’s most-favored-nation drug pricing agreement, one of the president’s most highly publicized affordability initiatives to bring down the cost of prescription drugs.
The president signed an executive order in May 2025 directing his administration to work toward securing most-favored-nation pricing with large pharmaceutical manufacturers. Most-favored-nation pricing means a manufacturer has agreed to sell some of its products in the U.S. at no higher a price than the lowest price among its economic peers. Since the order’s signing, the administration has announced deals to that effect with 26 of the largest pharmaceutical manufacturers in the world, as of Monday.
Monday’s group were more mid-sized pharmaceutical companies, according to the White House, though some can still be found on Drug Discovery & Development’s list of the 50 largest pharmaceutical companies. They are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB.
Trump said the deals would collectively save Americans hundreds of billions of dollars on prescription drugs and that there were more to come.
“In total, these agreements are projected to save Americans more than $600 billion over a very short period of time,” Trump said.
Other major pharmaceutical companies would soon follow suit, according to the president, as the deals that have been made cover approximately 89% of the branded drug market, according to a statement released by the White House.
Many of the companies that have entered into such agreements with the administration have agreed to sell a portion of their existing products or some of their most popular drugs to state Medicaid programs at MFN pricing. They have also agreed to sell certain products on the government’s direct-to-consumer online prescription drug marketplace, TrumpRx, at MFN pricing. People who purchase drugs on TrumpRx cannot use medical insurance. The companies have also agreed to offer all new, innovative medicines at MFN pricing.
All of the contracts, however, still remain unpublished and many questions remain about specifics and implementation. Consumer advocacy organization Public Citizen, which is already locked in dozens of lawsuits against the administration over a wide range of issues, announced it is working to obtain copies of the latest deals to resolve some of those questions.
Commented